Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of the Rheumatic Diseases

Topics

Medicine

Pathology

Internal Medicine

Hematology

Surgery

Show all topics

DOI

10.1136/annrheumdis-2016-210105

License

CC-BY-NC

Other Formats

PDF